CRISPR Therapeutics AG

Youtube Subscribe

Open: 79.54 Close: 78.92 Change: -0.62

Our AI found some flaws in CRISPR Therapeutics AG.

Are looking for the most relevant information about CRISPR Therapeutics AG? Investor spend a lot of time searching for information to make investment decisions in CRISPR Therapeutics AG. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about CRISPR Therapeutics AG are: Therapeutics, AG, share, CRISPR, Shares, LLC, approve, and the most common words in the summary are: stock, therapeutic, crispr, market, company, top, price, . One of the sentences in the summary was: CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Van …

Concept Map

Semantic Network

Stock Summary

CRISPR Therapeutics AG focuses on developing gene-based medicines for serious diseases. Its lead product candidate is CTX001, an ex vivo CRISpr gene-edited therapy for treating patients suffering from transfusion-dependent beta.

Today's Summary

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Van ECK Associates Corp reporter.am.am. Swiss National Bank and Headlands Technologies LLC Purchases New Stake in CRISpr Therapeutic AG.

Today's News

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Van ECK Associates Corp reporter.am. Swiss National Bank and Headlands Technologies LLC Purchases New Stake in CRISpr Therapeutic AG. Crispr Therapeutics AG ( NASDAQ: CRSP) shares ended trading in the red for the eighth consecutive day on Friday. Shares of the gene-editing company moved sideways after FDA approved Casgevy. 4,427 shares in crispr therapeutics ag (nasdaq:crsp) acquired by envestnet portfolio solutions inc. - defense world.com. Rafferty Asset Management LLC increased its position in shares of CRISPR Therapeutics by 28.9% during the third quarter. The European Commission approved two therapies for progressive, genetic diseases.

Stock Profile

"CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland."

Keywords

The game is changing. There is a new strategy to evaluate CRISPR Therapeutics AG fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about CRISPR Therapeutics AG are: Therapeutics, AG, share, CRISPR, Shares, LLC, approve, and the most common words in the summary are: stock, therapeutic, crispr, market, company, top, price, . One of the sentences in the summary was: CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Van ECK Associates Corp reporter.am.am. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #stock #therapeutic #crispr #market #company #top #price.

Read more →

Youtube Subscribe

---